Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Capital Employed (2016 - 2026)

Gyre Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 2.1% for Q4 2025.

  • Quarterly Return on Capital Employed fell 1318.0% to 2.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.1% through Dec 2025, down 1318.0% year-over-year, with the annual reading at 2.38% for FY2025, 1355.0% down from the prior year.
  • Return on Capital Employed was 2.1% for Q4 2025 at Gyre Therapeutics, down from 8.59% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 68.07% in Q1 2023 and troughed at 230.48% in Q1 2022.
  • The 5-year median for Return on Capital Employed is 39.49% (2024), against an average of 50.03%.
  • The largest YoY upside for Return on Capital Employed was 29855bps in 2023 against a maximum downside of -17577bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 166.04% in 2021, then soared by 112bps to 20.16% in 2022, then plummeted by -872bps to 155.61% in 2023, then soared by 110bps to 15.28% in 2024, then crashed by -86bps to 2.1% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Return on Capital Employed are 2.1% (Q4 2025), 8.59% (Q3 2025), and 7.52% (Q2 2025).